Kiji Therapeutics’ CEO Miguel Forte says that investment in cell and gene therapies might take a hit in light of ongoing global “turmoil” but he remains confident in the future of advanced therapies.
The EU Health Technology Assessment Regulation is based on the right principles, according to Forte, and a “pragmatic approach” must be applied to its implementation.
He applauded the European Commission for its plans to make the “hospital exemption” provision for ATMPs more transparent under its proposed review of the pharmaceutical legislation.

Kiji CEO On EU HTA Regulation, Hospital Exemption And The Future Of ATMPs

More from Interviews